AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
Recruiting
Observational Study
Hepatecellular Carcinoma
Hepatectomy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Observational
- Participants needed
- 353 (estimated)
- Sponsor
- Tongji Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This observational study aims to validate a deep learning model for predicting aggressive recurrence patterns in patients with early-stage liver cancer (HCC) after surgery.
The main question it aims to answer is: Can the AI model accurately identify patients at high risk of cancer recurrence within 2 years after surgery? Participants will provide clinical data and undergo standard surgery, follow…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Aged 18-75 years, regardless of gender.
* BCLC stage 0-A, scheduled for curative liver resection.
* Preoperative clinical diagnosis of hepatocellular carcinoma (HCC).
* Availability of dynamic contrast-enhanced MRI within 1 month before surgery, with acceptable image quality.
…
Contacts